Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Alzheimer’s drug Leqembi (lecanemab) is reportedly offering hope for patients in the early stages of the disease despite it ...

Leqembi's rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and ...

Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Acral Lentiginous Melanoma.

Foscenvivint is under development for the treatment of HCV or HBV or NASH-induced decompensated cirrhosis, leukemia such as acute myeloid leukemia (AML), neuroendocrine tumors, ch ...

PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the ...

The European Organization for Research and Treatment of Cancer (EORTC), a network of 3,800 members across 50 countries, is ...

Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act.

New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues Inducement GrantsBoston ...

JonesTrading analyst Soumit Roy reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) today and set a price ...